A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a
Read more** A pause in the heady stream of M&A headlines around the European healthcare sector & earnings season shines the spotlight on 7-year high valuations. ** Deal-making and the popularity of defensives have made sector a big draw for investors this year second only to utilities. http://link.r
Read moreBarclays: Credit Suisse cuts target price from 275p to 235p retaining a neutral rating. Barratt Developments: Liberum Capital reduces target price from 468p to 387p and downgrades to hold. Bellway: Liberum Capital reduces target price from 1900p to 1764p, while leaving its buy recommendation uncha
Read moreAntofagasta: Canaccord Genuity cuts target price from 870p to 835p and maintains a hold recommendation. African Minerals: Canaccord Genuity reduces target price from 230p to 170p and keeps a buy recommendation. Ashmore Group: Goldman Sachs downgrades to neutral with a target price of 430p. Barcla
Read moreNews that Shire has rejected a £27bn approach by AbbVie sent shares in the pharmaceutical and healthcare equipment sectors higher on Friday as yet more M&A continued to give sentiment a boost. "A bit of M&A excitement has been just the ticket to enliven trading on what may otherwise have been somet
Read moreLONDON (Alliance News) - Hikma Pharmaceuticals PLC Thursday said Chairman Said Darwazah exercised options over 75,924 shares at no cost under a company share plan Thursday. Following this transaction, Darwazah has a total holding of 11 million shares, which represents 5.51% stake in the fir
Read moreLONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning:
----------
FTSE 100
----------
TRADERS: CREDIT SUISSE CUTS NATIONAL GRID TO 'NEUTRAL' ('OUTPERFORM')
----------
BERENBERG RAISES LEGAL & GENER
Banknote printer De La Rue rose after it posted a 43% jump in full-year underlying operating profit and said it has entered the new financial year with a good order book. Helping it higher was Investec, which upped its target price from 890p to 915p and left its 'buy' recommendation unaltered. Al
Read moreHikma Pharmaceuticals has agreed to acquire certain key assets of the Bedford Laboratories generic injectables business from US-based Ben Venue Laboratories for up to 300m dollars. The purchase will be made for an initial $225m upfront cash payment as well as up to a further $75m in contingent cash
Read moreLONDON (Alliance News) - Hikma Pharmaceuticals PLC Wednesday said it has agreed to purchase the assets of Ben Venue Laboratories Inc's US generic injectables business for up to USD300.0 million, in a move to strengthen its position in the area. In a statement, Hikma said it will pay USD225.
Read more